| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Executive Chair | President &CEO | Director
2 companies
Loy Bertrand is an Executive Chair at Entegris, Inc. with holdings across 2 companies. Recent SEC Form 4 filings include 7 buys and 27 sells.
Estimated insider holdings value: $40.5M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | ENTG Entegris, Inc. | Executive Chair | Sale+OE | 44,138 | $144.41 | $6,373,968.58 | -16.2% | - | - | |
| Feb 25, 2026 | ENTG Entegris, Inc. | Executive Chair | Sale+OE | 109,838 | $138.25 | $15,185,007.99 | -5.4% | - | - | |
| Dec 1, 2025 | ENTG Entegris Inc | Executive Chair | Sale+OE | 57,570 | $76.88 | $4,425,994.50 | -5.7% | +77.6% | - | |
| Jul 3, 2024 | ENTG Entegris Inc | President &CEO | Sale+OE | 27,044 | $140.63 | $3,803,148.71 | -3.3% | -22.0% | -38.4% | |
| Aug 26, 2022 | HBIO Harvard Bioscience Inc | Director | Buy | 9,291 | $3.41 | $31,682.31 | +2.4% | -26.7% | +31.0% | |
| Aug 25, 2022 | HBIO Harvard Bioscience Inc | Director | Buy | 25,535 | $3.27 | $83,384.89 | +3.4% | -28.2% | +26.8% | |
| Aug 23, 2022 | HBIO Harvard Bioscience Inc | Director | Buy | 13,857 | $3.21 | $44,413.85 | +2.0% | -29.3% | +33.1% | |
| Aug 19, 2022 | HBIO Harvard Bioscience Inc | Director | Buy | 10,759 | $3.27 | $35,185.93 | +1.6% | -28.0% | +30.8% | |
| Aug 11, 2021 | ENTG Entegris Inc | President &CEO | Sell | 23,710 | $116.66 | $2,766,023.58 | -62.8% | +27.8% | -12.2% | |
| Aug 10, 2021 | ENTG Entegris Inc | President &CEO | Sell | 139,806 | $120.81 | $16,890,401.79 | -15.7% | +23.4% | -13.6% |